ridm@nrct.go.th   ระบบคลังข้อมูลงานวิจัยไทย   รายการโปรดที่คุณเลือกไว้

Long-term hepatitis B virus (HBV) response to Lamivudine-containing highly active antiretroviral therapy in HIV-HBV co-infected patients in Thailand

หน่วยงาน มหาวิทยาลัยเชียงใหม่

รายละเอียด

ชื่อเรื่อง : Long-term hepatitis B virus (HBV) response to Lamivudine-containing highly active antiretroviral therapy in HIV-HBV co-infected patients in Thailand
นักวิจัย : Khamduang W. , Gaudy-Graffin C. , Ngo-Giang-Huong N. , Jourdain G. , Moreau A. , Luekamlung N. , Halue G. , Buranawanitchakorn Y. , Kunkongkapan S. , Buranabanjasatean S. , Lallemant M. , Sirirungsi W. , Goudeau A.
คำค้น : -
หน่วยงาน : มหาวิทยาลัยเชียงใหม่
ผู้ร่วมงาน : -
ปีพิมพ์ : 2555
อ้างอิง : 19326203 , 10.1371/journal.pone.0042184 , http://www.scopus.com/inward/record.url?eid=2-s2.0-84864447642&partnerID=40&md5=2632dd8bd211cd6a59b788d3572a98b1 , http://cmuir.cmu.ac.th/handle/6653943832/888
ที่มา : -
ความเชี่ยวชาญ : -
ความสัมพันธ์ : -
ขอบเขตของเนื้อหา : -
บทคัดย่อ/คำอธิบาย :

Background: Approximately 4 million of people are co-infected with HIV and Hepatitis B virus (HBV). In resource-limited settings, the majority of HIV-infected patients initiate first-line highly active antiretroviral therapy containing lamivudine (3TC-containing-HAART) and long-term virological response of HBV to lamivudine-containing HAART in co-infected patients is not well known. Methodology/Principal Finding: HIV-HBV co-infected patients enrolled in the PHPT cohort (ClinicalTrials.gov NCT00433030) and initiating a 3TC-containing-HAART regimen were included. HBV-DNA, HIV-RNA, CD4+ T-cell counts and alanine transaminase were measured at baseline, 3 months, 12 months and then every 6 months up to 5 years. Kaplan-Meier analysis was used to estimate the cumulative rates of patients who achieved and maintained HBV-DNA suppression. Of 30 co-infected patients, 19 were positive for HBe antigen (HBeAg). At initiation of 3TC-containing-HAART, median HBV DNA and HIV RNA levels were 7.35 log 10 IU/mL and 4.47 log 10 copies/mL, respectively. At 12 months, 67% of patients achieved HBV DNA suppression: 100% of HBeAg-negative patients and 47% of HBeAg-positive. Seventy-three percent of patients had HIV RNA below 50 copies/mL. The cumulative rates of maintained HBV-DNA suppression among the 23 patients who achieved HBV-DNA suppression were 91%, 87%, and 80% at 1, 2, and 4 years respectively. Of 17 patients who maintained HBV-DNA suppression while still on 3TC, 4 (24%) lost HBsAg and 7 of 8 (88%) HBeAg-positive patients lost HBeAg at their last visit (median duration, 59 months). HBV breakthrough was observed only in HBeAg-positive patients and 6 of 7 patients presenting HBV breakthrough had the rtM204I/V mutations associated with 3TC resistance along with rtL180M and/or rtV173L. Conclusions: All HBeAg-negative patients and 63% of HBeAg-positive HIV-HBV co-infected patients achieved long-term HBV DNA suppression while on 3TC-containing-HAART. This study provides information useful for the management of co-infected patients in resource-limited countries where the vast majority of co-infected patients are currently receiving 3TC. © 2012 Khamduang et al.

บรรณานุกรม :
Khamduang W. , Gaudy-Graffin C. , Ngo-Giang-Huong N. , Jourdain G. , Moreau A. , Luekamlung N. , Halue G. , Buranawanitchakorn Y. , Kunkongkapan S. , Buranabanjasatean S. , Lallemant M. , Sirirungsi W. , Goudeau A. . (2555). Long-term hepatitis B virus (HBV) response to Lamivudine-containing highly active antiretroviral therapy in HIV-HBV co-infected patients in Thailand.
    เชียงใหม่ : มหาวิทยาลัยเชียงใหม่ .
Khamduang W. , Gaudy-Graffin C. , Ngo-Giang-Huong N. , Jourdain G. , Moreau A. , Luekamlung N. , Halue G. , Buranawanitchakorn Y. , Kunkongkapan S. , Buranabanjasatean S. , Lallemant M. , Sirirungsi W. , Goudeau A. . 2555. "Long-term hepatitis B virus (HBV) response to Lamivudine-containing highly active antiretroviral therapy in HIV-HBV co-infected patients in Thailand".
    เชียงใหม่ : มหาวิทยาลัยเชียงใหม่ .
Khamduang W. , Gaudy-Graffin C. , Ngo-Giang-Huong N. , Jourdain G. , Moreau A. , Luekamlung N. , Halue G. , Buranawanitchakorn Y. , Kunkongkapan S. , Buranabanjasatean S. , Lallemant M. , Sirirungsi W. , Goudeau A. . "Long-term hepatitis B virus (HBV) response to Lamivudine-containing highly active antiretroviral therapy in HIV-HBV co-infected patients in Thailand."
    เชียงใหม่ : มหาวิทยาลัยเชียงใหม่ , 2555. Print.
Khamduang W. , Gaudy-Graffin C. , Ngo-Giang-Huong N. , Jourdain G. , Moreau A. , Luekamlung N. , Halue G. , Buranawanitchakorn Y. , Kunkongkapan S. , Buranabanjasatean S. , Lallemant M. , Sirirungsi W. , Goudeau A. . Long-term hepatitis B virus (HBV) response to Lamivudine-containing highly active antiretroviral therapy in HIV-HBV co-infected patients in Thailand. เชียงใหม่ : มหาวิทยาลัยเชียงใหม่ ; 2555.